News

To ensure that VITAL Online remains up to date with best practice technology the Allergen Bureau will shortly be introducing multifactor authentication to your VITAL Online log in. Just like your banking system, by using recognised Authenticators like Google Authenticator…

Aravax is a Melbourne-based biotechnology company developing the first precisely targeted immunotherapeutic for peanut allergy, PVX108. An investment of US$20m from Australian investors, Brandon Capital and Tenmile will support Phase 2 trials. PVX108 does not contain peanut protein but is…

Cowpea (Vigna unguiculata) is a legume that is widely cultivated and very important for the nutrition and health of millions of people, particularly in Africa, Asia, South America, and Southern Europe. Cowpea is emerging as a low-cost alternative protein in…

While peanuts contain 17 known allergenic proteins, previous research has shown that boiling peanuts appears to reduce their allergenicity by changing the protein structure. Now, in an Australian clinical trial, 80 per cent of children enrolled in the study were…

The Journal of Allergy and Clinical Immunology: In Practice has celebrated its first 10 years in 2023. To celebrate, the journal’s editorial team has looked into past and the future, speculating what developments we might expect over the next decade.…

The United States Food and Drug Administration (US FDA) has updated its allergen labelling guidance with new and revised questions and answers. The update replaces previous advice released in 2006 and reflects new information, including the requirement to label sesame which comes…